NEPTUNUS(SZ:000078) Shang Hai Zheng Quan Bao·2025-12-07 18:48Core Viewpoint - The stock price of Shenzhen Haiwang Biological Engineering Co., Ltd. has experienced significant fluctuations, with a cumulative increase of over 100% in the closing price over eight consecutive trading days, indicating severe abnormal trading conditions [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% over three consecutive trading days from December 3 to December 5, 2025, qualifying as an abnormal trading fluctuation [2][4]. - The stock's price deviation reached a cumulative increase of 105.64% over eight trading days from November 26 to December 5, 2025, indicating severe abnormal trading conditions [11]. Group 2: Company Financial Performance - In 2024, the company achieved a revenue of 30.317 billion yuan, with a net loss attributable to shareholders of 1.193 billion yuan [3]. - For the first three quarters of 2025, the company reported a revenue of 21.513 billion yuan and a net profit of 25.703 million yuan [3]. Group 3: Company Operations and Information Disclosure - The company has confirmed that there are no undisclosed significant matters that should have been disclosed according to the Shenzhen Stock Exchange regulations [10]. - The company has not identified any major changes in its production and operational conditions, and the internal and external business environment remains stable [7].